Back to results
US 2015/0306191 A1Published application
Vaccine
AssigneeAffiris AG
InventorsSylvia BRUNNER, Gergana GALABOVA, Gabriele WINSAUER, Erika BILCIKOVA, Claudia JUNO, Pola LINZMAYER-HIRT, Birgit SCHUH, Guenther STAFFLER
Life of this patent
Estimating the term…
Abstract
The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.
Claims15
Vaccine comprising at least one peptide consisting of 9 to 25 amino acid residues having the amino acid sequence
- (SEQ ID No. 1)
- X1X2X3WX4X5X6RX7(X8)m(X9)n,
- wherein
- X1 is an amino acid residue selected from the group of uncharged amino acid residues, preferably selected from the group consisting of serine, threonine, valine and alanine,
- X2 is an amino acid residue selected from the group of uncharged amino acid residues, preferably selected from the group of isoleucine, valine, glycine, glutamine and alanine, more preferably isoleucine, valine, glutamine and alanine.
- X3 is an amino acid residue selected from the group of uncharged amino acid residues, preferably selected from the group consisting of proline, threonine, alanine and valine, more preferably proline,
- X4 is an amino acid residue selected from the group consisting of asparagine, serine, alanine, glutamine and aspartic acid,
- X5 is an amino acid residue selected from the group consisting of leucine, glycine, alanine, tyrosine, aspartic acid, phenylalanine and valine, preferably leucine,
- X6 is an amino acid residue selected from the group of hydrophilic, negatively charged amino acid residue, preferably an amino acid residue selected from the group consisting of glutamic acid and aspartic acid,
- X7 is an amino acid residue selected from the group of uncharged amino acid residues, preferably selected from the group consisting of isoleucine, leucine, alanine and threonine,
- X8 is an amino acid residue selected from the group of uncharged amino acid residues selected from the group consisting of threonine, leucine, glutamine, alanine and serine,
- X9 is X10X11X12 or a C-terminal truncated fragment thereof consisting of 1 or 2 amino acid residues,
- X10 is any amino acid residue, preferably an amino acid residue selected from the group of uncharged amino acid residues, preferably selected from the group consisting of proline, alanine and serine,
- X11 is any amino acid residue, preferably an amino acid residue selected from the group of uncharged amino acid residues, preferably selected from the group consisting of proline, alanine, valine, threonine and asparagine,
- X12 is any amino acid residue, preferably an amino acid residue selected from the group consisting of arginine, alanine, lysine, serine and leucine,
- m is 0 or 1,
- n is 0 or 1, and
- SEQ ID No. 1 is not SIPWNLERITPPR or a C-terminal truncated fragment thereof,
- wherein said at least one peptide is coupled or fused to a pharmaceutically acceptable carrier.
16 more elements
Dependencies are inferred from the claim text.